Intranasal antihistamine gains marketing approval.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D017277:Drug Approval; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010793:Phthalazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
D006634:Histamine H1 Antagonists; D010793:Phthalazines; C020976:azelastine